Product Description
| Cat Number | SPR-405B |
|---|---|
| Category | Recombinant Protein |
| Pack Size | 100 µg |
| Description | Human Recombinant Beta Synuclein Protein Monomers |
| Applications | WB | SDS-PAGE | In vivo assay | In vitro assay |
| Target | Beta Synuclein |
| Molecular Weight | 14.28 kDa |
| Cellular Localization | Cytoplasm |
| Purity | >95% |
| Research Area | Neuroscience | Neurodegeneration | Alzheimer's Disease | Tangles & Tau | Neuroscience | Neurodegeneration | Parkinson's Disease | Synuclein |
| Swiss Prot | Q16143 |
| Scientific Background | Alzheimer’s Disease (AD) is the most common neurodegenerative disease, affecting 10% of seniors over the age of 65 (1). It was named after Alois Alzheimer, a German scientist who discovered tangled bundles of fibrils where neurons had once been in the brain of a deceased patient in 1907 (2). Beta synuclein is abundant in neurofibrillary lesions of patients with Alzheimer's Disease. Beta synuclein is suggested to be an inhibitor of alpha synuclein aggregation- protecting the central nervous system from the neurotoxin effects of alpha synuclein (3). |
| Expression System | E. coli |
| Accession Number | NP_001001502.1 |
| Gene Id | 6620 |
| Protein Length | Full length |
| Purification | Ion-exchange Purified |
| Storage | -80ºC |
| References | 1. www.alz.org/alzheimers-dementia/facts-figures 2. Alzheimer, A. Über eine eigenartige Erkrankung der Hirnrinde. Allg. Z. Psychiatr. Psych.-Gerichtl. Med. 64, 146–148 (1907). 3. Taschenberger G., et al. (2013) Ann Neurol. 74(1): 109-118. |
| Product Url | View Document |
| Note | The product is for research use only |
Share Item: